Dr. Manda Speaks to Ecancer About the Study he Presented During the EHA 2020 Virtual Meeting

6/15/2020

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Dr. Sudhir Manda presents the US MM-6 study, a community-based study looking at long-term proteasome inhibition in multiple myeloma (MM) following an in-class transition from bortezomib (btz) to ixazomib (ixa).

Dr. Manda gives a detailed account of the trial design, results, and the ongoing enrollment status of this clinical trial. He finalizes by explaining what clinical and patient impact this research will have.

Watch the video here.